Pricing Log in Create free account

Nektar Therapeutics (NKTR) vs Urogen Pharma (URGN)

Nektar Therapeutics and Urogen Pharma are both Biotechnology companies. Nektar Therapeutics and Urogen Pharma are of similar size ($1.3B and $1.2B). Urogen Pharma grew revenue faster over the last twelve months: 159.3% against −27.2%. Urogen Pharma has the higher net margin (−26.3% vs −287.8%) and the higher return on invested capital (0.00% vs −40.2%). Across the 17 metrics below, Urogen Pharma leads on 14 and Nektar Therapeutics on 3.

Valuation

Metric NKTR URGN Biotechnology median
P/E n/m n/m 10.60
P/S 22.56 5.01 9.40
P/B 1.36 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 19.22 5.41 9.02
Earnings yield (17.99%) (5.32%) (32.88%)
Free cash flow yield (19.01%) (10.53%) (23.13%)

Profitability

Metric NKTR URGN Biotechnology median
Gross margin 100.00% 91.41% 68.51%
Operating margin (257.80%) (12.36%) 0.00%
Net margin (287.84%) (26.27%) 0.00%
Free cash flow margin (428.72%) (52.77%) 0.00%
Return on equity (35.75%) 54.65% (51.96%)
Return on assets (24.12%) (28.78%) (46.06%)
Return on invested capital (40.20%) 0.00% 0.00%

Growth

Metric NKTR URGN Biotechnology median
Revenue growth (TTM) (27.15%) 159.29% 6.76%
EPS growth (last fiscal year) (11.89%) (7.77%) 29.88%
Revenue growth, 5-year CAGR (18.43%) 56.22% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NKTR URGN Biotechnology median
Debt to equity 0.00 (1.53) 0.00
Current ratio 10.42 3.40 4.97
Net debt to EBITDA 1.77 0.00 1.01

Dividend

Metric NKTR URGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric NKTR URGN Biotechnology median
Market cap 1.23b 1.26b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack